Clinical Trial Update: Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma [Phase 1, Phase 2]

View source ↗

Summary

A study evaluating radium-223 dichloride in relapsed multiple myeloma was terminated; results were posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Radium-223 dichloride (radium-223 dichloride)

Snippet

Sponsor: Bayer | Conditions: Multiple Myeloma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2020-02-26